Literature DB >> 10744090

QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.

J G Reilly1, S A Ayis, I N Ferrier, S J Jones, S H Thomas.   

Abstract

BACKGROUND: Sudden unexplained death in psychiatric patients may be due to drug-induced arrhythmia, of which lengthening of the rate-corrected QT interval (QTc) on the electrocardiogram is a predictive marker. We estimated the point prevalence of QTc lengthening in psychiatric patients and the effects of various psychotropic drugs.
METHODS: Electrocardiograms were obtained from 101 healthy reference individuals and 495 psychiatric patients in various inpatient and community settings and were analysed with a previously validated digitiser technique. Patients with and without QTc lengthening, QTc dispersion, and T-wave abnormality were compared by logistic regression to calculate odds ratios for predictive variables.
FINDINGS: Abnormal QTc was defined from the healthy reference group as more than 456 ms and was present in 8% (40 of 495) of patients. Age over 65 years (odds ratio 3.0 [95% CI 1.1-8.3]), use of tricyclic antidepressants (4.4 [1.6-12.1]), thioridazine (5.4 [2.0-13.7]), and droperidol (6.7 [1.8-24.8]) were robust predictors of QTc lengthening, as was antipsychotic dose (high dose 5.3 [1.2-24.4]; very high dose 8.2 [1.5-43.6]). Abnormal QT dispersion or T-wave abnormalities were not significantly associated with antipsychotic treatment, but were associated with lithium therapy.
INTERPRETATION: Antipsychotic drugs cause QTc lengthening in a dose-related manner. Risks are substantially higher for thioridazine and droperidol. These drugs may therefore confer an increased risk of drug-induced arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10744090     DOI: 10.1016/s0140-6736(00)02035-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  116 in total

Review 1.  Treatment-refractory schizophrenia.

Authors:  P F Buckley; L D Wiggins; S Sebastian; B Singer
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

2.  Weighing the QT intervals with the slope or the amplitude of the T wave.

Authors:  Kaspar Lund; Hans Nygaard; Anders Kirstein Pedersen
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-01       Impact factor: 1.468

3.  Removal of thioridazine from primary care formulary will result in prescribing vacuum.

Authors:  N Wright
Journal:  BMJ       Date:  2001-09-22

4.  QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.

Authors:  Adrián LLerena; Roland Berecz; Alfredo de la Rubia; Pedro Dorado
Journal:  Eur J Clin Pharmacol       Date:  2002-06       Impact factor: 2.953

Review 5.  Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs.

Authors:  Simon J C Davies; Leila B Cooke; Alan G Moore; John Potokar
Journal:  BMJ       Date:  2002-06-22

Review 6.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Effects of licence change on prescribing and poisons enquiries for antipsychotic agents in England and Scotland.

Authors:  D N Bateman; A M Good; R Afshari; C A Kelly
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

8.  Knowledge deficits related to the QT interval could affect patient safety.

Authors:  Nancy M Allen LaPointe; Sana M Al-Khatib; Judith M Kramer; Robert M Califf
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-04       Impact factor: 1.468

9.  Impact of the CSM advice on thioridazine on general practitioner prescribing behaviour in Leeds: time series analysis.

Authors:  Nat M J Wright; Alison J Roberts; Victoria L Allgar; Charlotte N E Tompkins; Darren C Greenwood; Gillian Laurence
Journal:  Br J Gen Pract       Date:  2004-05       Impact factor: 5.386

Review 10.  Thioridazine: resurrection as an antimicrobial agent?

Authors:  H K R Thanacoody
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.